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ablation line reduces recurrence of atrial ﬁbrillation (AF) or atrial tachycardia (AT) after radiofrequency catheter
ablation.Background AF/AT recurrence is common after pulmonary vein isolation (PVI).Methods We included 102 patients from 2 centers (age 63  10 years; 33 women; left atrium 38  7 mm; left ventricular
ejection fraction 61  6%) with symptomatic paroxysmal AF. A 3-dimensional mapping system and circumferential
mapping catheter were used in all patients for PVI. In group 1 (n ¼ 50), the procedural endpoint was bidirectional
block across the ablation line. In group 2 (n ¼ 52), additional UE to bipolar pacing at an output of 10 mA and 2-ms
pulse width was required. The primary endpoint was freedom from any AF/AT (>30 s) after discontinuation of
antiarrhythmic drugs.Results Procedural endpoints were successfully achieved in all patients. Procedure duration was signiﬁcantly longer in group
2 (185  58 min vs. 139  57 min; p < 0.001); however, ﬂuoroscopy times were not different (23  9 min vs.
23  9 min; p ¼ 0.49). After a follow-up of 12 months in all patients, 26 patients (52%) in group 1 versus 43
(82.7%) in group 2 were free from any AF/AT (p¼ 0.001) after a single procedure. No major complications occurred.Conclusions The use of pacing to ensure UE along the PVI line markedly improved near-term single-procedure success, compared
with demonstration of bidirectional block alone. This additional endpoint signiﬁcantly improved patient outcomes
after PVI. (Unexcitability Along the Ablation as an Endpoint for Atrial Fibrillation Ablation; NCT01724437) (J Am
Coll Cardiol 2013;62:44–50) ª 2013 by the American College of Cardiology FoundationBecause ectopy from the pulmonary veins is primarily
responsible for initiation and maintenance of paroxysmal
atrial ﬁbrillation (PAF), pulmonary vein isolation (PVI) has
become the standard treatment of this arrhythmia (1–3).
Arrhythmia recurrence is high, however, especially during
longer follow-up (4). Data suggest that dormant conduction
gaps on the ablation line are the most common reasons for
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, 2012; revised manuscript received March 9,to decrease the likelihood of conduction gaps using point-
by-point catheter ablation technology has been reported in
a prospective, randomized trial. Previously published results
suggest that additional radiofrequency (RF) application
guided by atrial tissue excitability may be helpful to identify
potential conduction gaps in atrial myocardium (7,8). The
present prospective, randomized 2-center trial was con-
ducted to evaluate whether the endpoint of unexcitability
along the ablation line is as safe and more effective in pre-
venting arrhythmia recurrence than electrical PVI alone.
The aim of the study was to assess the near-term
(12 months) efﬁcacy of PVI using a standard approach
compared with application of an additional acute procedural
endpoint of unexcitability along the ablation line.
Methods
Study population. A total of 103 patients (age 63 10 years;
34 women; left atrium [LA] 38  7 mm; left ventricular ejec-
tion fraction 61  6%) referred for catheter ablation for
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PVI = pulmonary vein
isolation
RF = radiofrequency
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45symptomatic PAF who had failed at least 1 type I or III
antiarrhythmic drug were included in our study. One patient
withdrew written informed consent. Ablation was per-
formed in one of 2 participating centers (University Hospital,
Hamburg, Germany, or Brigham and Women’s Hospital,
Boston, Massachusetts) by 1 of 3 surgeons during sinus
rhythm in all patients. Randomization to either study arm
was conducted before the procedure based on a previously
generated computer algorithm (Fig. 1). No patients had
evidence of signiﬁcant structural heart disease (see next
section) as assessed by at least 1 imaging study such as
echocardiography, computed tomography scan, or magnetic
resonance imaging. Baseline parameters are shown in
Table 1. There were no statistically signiﬁcant differences
between groups.
Study inclusion/exclusion criteria. Patients were eligible
for the study if they: 1) were able and willing to give written,
informed consent; 2) had a history of symptomatic PAF
(episode duration <48 h; 3) had no prior electrical car-
dioversion in the year before study inclusion; 4) at least 1
class I or III antiarrhythmic drug had failed; and 5) pre-
sented in sinus rhythm. Exclusion criteria consisted of: 1)
age <18 years; 2) structural heart disease (hypertrophic
cardiomyopathy [septal thickness >13mm], left ventricular
ejection fraction 35%, signiﬁcant valvular heart disease,
LA size >50 mm); 3) reversible causes of AF; 4) intracardiac
thrombus; and 5) inability to take warfarin.
Electrophysiological study and ablation procedure. The
patients underwent electrophysiological study and catheter
ablation after providing written informed consent. Study
protocols were approved by the Brigham and Women’s
Hospital Human Subject Protection Committee and the
Ethical Board Committee of the Ethical Committee of
the Medical Association, Hamburg, Germany. All antiar-
rhythmic drugs except amiodarone were stopped a minimum
of 5 half-lives prior to the procedure.Figure 1 Study Flow Chart
AF ¼ atrial ﬁbrillation; AT ¼ atrial tachycardia; CMC ¼ circumferential mapping
catheter; PAF ¼ paroxysmal atrial ﬁbrillation.Surface and intracardiac elec-
trocardiograms (ECGs) were digi-
tally recorded and stored (Prucka
CardioLab EP system, GE
Healthcare, Waukesha, Wiscon-
sin; LabSystem Pro EP recording
system, BARD Electrophysi-
ology, Lowell, Massachusetts).
Nonﬂuoroscopic 3-dimensional
mapping was performed using
the Carto (Biosense Webster,
Diamond Bar, California) or
Ensite NavX (St. Jude Medical,
St. Paul, Minnesota) system at
the operator’s discretion.
A 7-F multipolar (20-pole)catheter (Daig DuoDeca 2-10-2, St. Jude Medical, or
Ismus, Biosense Webster) was used with the distal poles
(poles 1 to 10) placed within the coronary sinus and the
proximal electrodes (poles 11 to 20) located along the
tricuspid annulus in the lateral and inferior right atrium. In
some cases, the duodecapolar catheter was introduced
through a long guiding sheath (Convoy 55 curve, Boston
Scientiﬁc, Natick, Massachusetts) to facilitate placement and
stability. Alternatively, a 6-F decapolar catheter (St. Jude
Medical) was placed within the coronary sinus. A 10- or
20-pole circumferential PV mapping catheter (Optima,
Irvine Biomedical, Irvine, California, or Lasso, Biosense
Webster) was positioned at the ostium of one of the ipsi-
lateral PVs, usually the superior vein, either before or after
PVI. To avoid potential bias with respect to conduction
breakthrough prior to PV entrance block, the circumferential
mapping catheter (CMC) signals were continuously recor-
ded but not displayed to the operators during deployment
of the ablation line or until atrial tissue directly on this line
was rendered unexcitable to pacing. The electrogram signals
from the CMC were then reviewed, and the catheter was
positioned to sequentially assess electrical isolation of the
ipsilateral PVs. Entrance block into PVs was conﬁrmed by
the complete absence of PV potentials and/or by retro-
spective review of the PV signals after each ablation lesion to
determine when entrance block was achieved. If far-ﬁeld
potentials were seen on the CMC, direct pacing of the
suspected far-ﬁeld source was performed for conﬁrmation.
Pacing along the ablation line was performed with careful
attention to avoid parallel orientation of the ablation catheter
tip to the tissue; this prevented inadvertent pace capture
from the proximal electrode of the distal bipole. During
LA ablation, heparin was administered intravenously to
maintain an activated clotting time of >300 s.
Ablation was performed using an open-irrigated 3.5-mm
tip mapping and ablation catheter (Thermocool, Biosense
Webster) advanced into the LA via a long sheath (SL0, 8-F,
St. Jude Medical) to mechanically support the ablation
catheter. Ablation lesions were generated in a power-
controlled mode applying 10 to 40 W for 30 to 60 s per
Table 1 Baseline and Procedural Data of Both Patient Groups
Conventional Group
(n ¼ 50)
Pace-Guided Group
(n ¼ 52)
Overall
(n ¼ 102) p Value
Female, n, (%) 15 (14.7) 18 (17.6) 33 (32.4) 0.675
Age, yrs 62.4  9.9 62.8  10.6 62.6  10.2 0.627
LA diameter, mm 39.8  6.6 37.0  5.6 38.0  7.0 0.13
LV function, % 62.2  6.2 62.8  10.6 61.1  6.1 0.158
AF history, months 60 (12–369) 50 (12–140) 60 (12–369) 0.231
Longest AF episode, h 12 (1–48) 9 (1–48) 10 (1–48) 0.205
Antiarrhythmic drugs, n 1 (0–2) 1 (0–3) 1 (0–3) 0.24
Amiodarone, n 18 10 28 0.082
Procedure duration, min 138.8  56.6 185.1  58.7 162.7  61.9 <0.001
Fluoroscopy time, min 22.5  9.3 24.8  8.9 23.7  9.1 0.177
RF duration, min 20.7  9.5 29.5  17.7 25.1  13.6 <0.001
Values are n (%), mean  SD, median (range), or n.
AF ¼ atrial ﬁbrillation; LA ¼ left atrial; LV ¼ left ventricular; RF ¼ radiofrequency.
Steven et al. JACC Vol. 62, No. 1, 2013
Pace Capture Loss as Pulmonary Vein Isolation Endpoint July 2, 2013:44–50
46lesion during irrigation at a rate of 17 to 30 ml/min. The
upper temperature limit was set to 45C. Esophageal posi-
tion was monitored ﬂuoroscopically after oral administration
of 5 ml of a barium sulfate esophageal cream (E-Z-EM,
Lake Success, New York) (8) or with the use of an esoph-
ageal temperature probe. RF power was reduced at sites
near the esophagus to 10 to 30 W; ablation at sites in
direct proximity to the esophagus was avoided, and ablation
was terminated before the esophageal temperature exceed-
ed 38.5C (9). Patients were administered either intrave-
nous conscious sedation (Hamburg) or general anesthesia
(Boston). The procedures consisted of PVI only. No infu-
sion of isoproterenol was administered nor were extra PV
ectopies observed or ablated in any patient. Patients with
documented typical right atrial ﬂutter underwent right atrial
isthmus ablation in the same session.
Three-dimensional mapping with registration of a previ-
ously performed imaging study (computed tomography scan
or magnetic resonance imaging) was used in all cases (Ensite
NavX or Carto). Ablation lesions were placed along the
antral circumference of the ipsilateral PVs 1 cm from the
PV ostia. At the anterior portion of the left pulmonary veins,
the ablation line was directed at the PV side of the LA
appendage (LAA) ridge.
Evaluation of unexcitability along the ablation line. When
the anatomic ablation line encircling the ipsilateral veins was
completed, pacing was performed during sinus rhythm on
the entire ablation line with pacing sites approximately
5 mm apart. Bipolar pacing between the 2 distal electrode
pairs of the ablation catheter was performed with a pacing
output set to 10 mA at a pulse width of 2 ms (8). Bipolar
pacing was chosen based on data from a pre-clinical study
that suggested greater predictive value of bipolar versus
unipolar loss of pace capture (9).
Catheter stability during pacing was validated by
observing the tip position on biplane ﬂuoroscopy and the
3-dimensional mapping system and by monitoring the
stability of local electrogram morphology. If atrial tissue
was still excitable to pacing at the predetermined output,additional ablation lesions were delivered until unexcitability
was achieved at that location. If atrial tissue along the line
was still excitable to pacing after RF applications of a dura-
tion totaling at least 60 s, RF application was continued
at adjacent sites until pacing capture no longer occurred in
the region.
Analysis of entrance and exit block from PVs. When
possible, the RF lesion associated with PV entrance block
during ablation line deployment was determined after
encircling RF ablation. PVI was prospectively conﬁrmed in
ipsilateral PVs by demonstrating failure of conduction into
the veins and local capture of PV potentials with exit block
from each PV. The amount of RF energy (Joules) delivered
beyond PV entrance block was calculated; these data were
not available for 15 of 102 patients.
Bipolar electrograms from the distal and ﬁrst ring elec-
trode with an interelectrode distance of 1 mm, ﬁltered at
30 to 500 Hz, were recorded from the mapping catheter
and stored on digital media (Prucka CardioLab EP or
LabSystem Pro EP). Catheter position at each pacing
site was marked on the 3-dimensional mapping system.
Atrial electrogram width (milliseconds) and amplitude
(milliamperes) were measured using electronic calipers
and grouped according to excitability or unexcitability at
the pre-determined pacing output using the stored proce-
dural data on the recording system in a subset of patients
(n ¼ 29).
For identiﬁcation of sites requiring additional RF appli-
cations, the ablation line was schematically divided into
8 segments. RF applications guided by pacing were then
assigned to the appropriate segments along the ablation line.
Follow-up. All patients were consistently seen by an elec-
trophysiologist every 3 months after the procedure for at
least 12 months. At each visit, 72-h Holter monitoring or
7-day auto-triggered event monitor was provided. After a
3-month blanking period, arrhythmia recurrence was
deﬁned as any episode of atrial tachycardia (AT) or AF
>30 s according to current expert consensus on AF ablation
(10). During the follow-up visits, current antiarrhythmic
Figure 2 Signal Amplitude and Signal Width for Sites With and Without Pacing Capture After RF
The mean for each group (signal amplitude [upper] and signal width [lower]) is indicated by the solid bar. Although there is a signiﬁcant difference in signal amplitude between
groups, substantial overlap exists. RF ¼ radiofrequency.
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47medications and symptoms of AF such as palpitations and
loss of exercise capacity were assessed.
Statistical analysis. Continuous variables are reported as
mean  SD or as median and range (minimum–maximum)
as appropriate. Comparison of continuous variables was
performed using the Student t test. Ordinal variables were
compared using the Mann-Whitney U test. Time to recur-
rence and event-free survival curves were calculated using
the Kaplan-Meier estimation method. A p value <0.05was considered statistically signiﬁcant. Calculations were
performed using the statistical software SPSS version 16.0 for
Macintosh (SPSS, Chicago, Illinois). Our sample size
calculation assumed 65% arrhythmia-free survival in patients
assigned to the conventional group and 35% arrhythmia-free
survival in patients assigned to the pace-guided group with
a sigma (SD) of 0.15. To detect this difference with a power
of 0.8 and an alpha level of 0.05, we calculated that
48 patients per arm should be included in the study.
Figure 3 Arrhythmia-Free Survival
Patients in the conventional group (dotted line, group 1) had a signiﬁcantly greater
AF/AT recurrence rate. Events during the ﬁrst 3 months were not counted
according to the blanking period. Abbreviations as in Figure 1.
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48Results
Patients and procedure. The baseline data of the 102
patients included to the study are given in Table 1. Fifty
patients (49%) were randomly assigned to conventional PVI
(group 1) and 52 (51%) to pace-guided PVI (group 2).
Procedure duration was signiﬁcantly longer in the pace-
guided group (185  59 min vs. 139  57 min; p < 0.001);
however, ﬂuoroscopy times were not signiﬁcantly different
(25  9 min vs. 23  9 min; p ¼ 0.177). In the conventional
group, entrance and exit block in the PV guided by a CMC
was reached in all patients. After achievement of unexcit-
ability in the pace-guided group, 49 of 50 (98%) left vein pairs
and 48 of 50 (96%) right vein pairs were isolated. The
remaining gaps were ablated with CMC guidance. In the
pace-guided group, 20 (40%) left pairs of veins showed
entrance block after anatomic completion of the ablation line
as opposed to 17 (34%) on the right side. Overall, after PV
potentials disappeared on the CMC, further ablation to
achieve the endpoint of unexcitability in the pace-guided
group added 13.7  12.7 kJ of RF energy to the procedure
(Table 1). Additional RF application was required in 93
of 104 pairs of veins after PVI and anatomic completion of
the line. Areas requiring signiﬁcantly more RF application
consisted of the superior portion of the right pulmonary
veins (p¼ 0.03) and the ridge between LAA and left superior
vein (p ¼ 0.02) compared with other areas along the line.
Analysis of the signal amplitude of regions that were tested
for capture at a pacing output of 10 mV at 2-ms pulse width
demonstrated a signiﬁcantly greater amplitude at capture
versus noncapture sites (0.25 0.32 mV vs. 0.17 0.25 mV;
p ¼ 0.008); however, voltages overlapped substantially for
capture versus noncapture sites (Fig. 2).
Modiﬁcation of the ablation line was necessary in
5 patients to avoid esophageal temperature rises.
Primary endpoint. All patients completed at least 12
months of follow-up. After a mean follow-up of 18  6
months, 26 patients (52%) in the conventional versus
43 (82.7%) in the pace-guided group were free from any
AF/AT episode lasting longer than 30 s after a single
procedure free from class I or III antiarrhythmic medications
(p ¼ 0.001). None of the patients had progression to
persistent AF during the follow-up. There was 1 stroke in
the CMC-guided group that resulted in a midterm com-
prehension and reading deﬁcit. No other further procedure-
related complications occurred. See Figure 3 for comparison
of AF/AT-free survival in the 2 groups.
Discussion
Main ﬁndings. In the present randomized study, we were
able to conﬁrm our ﬁndings from a pilot feasibility trial that
achieving and assessing unexcitability along the ablation line is
feasible and may serve as an additional endpoint for PVI
procedures.Wewere furthermore able to show that additional
ablation does not translate into higher risk for procedure-
related complications. Most remarkably, achievement ofunexcitability along the ablation line signiﬁcantly improved
freedom from AF/AT by almost 30% during a mean follow-
up of 18 months.
Prior studies. Electrical isolation of the PV has been
performed for more than a decade now (1). After initial PVI,
recurrences are unfortunately common.
Many studies have suggested that the main reason for AF
recurrence in patients with PAF is electrical reconnection of
the PVs after initially successful isolation (4,6). By extension,
permanent electrical isolation of the PVs at the initial
procedure would be expected to decrease arrhythmia recur-
rence. Different strategies have been used to improve
outcomes for patients with PAF, including the application
of a longer intraprocedural waiting period after electrical
PVI, administration of adenosine to reveal “dormant”
conduction, and the use of technological advances such as
“single-shot” devices, duty cycling multielectrode ablation
catheters, balloon catheters, and robotic navigation systems
to improve catheter contact (3,11–13). None of these
techniques or technologies have been shown to improve
outcomes compared with a “standard” point-by-point cath-
eter ablation guided by electrical PVI.
Recently Eitel et al. (7) reported that pacing during
ablation around PVs is safe and feasible to achieve good
midterm arrhythmia-free survival. Independently, we were
also able to show that rendering the ablation line unexcitable
to pacing is feasible and may serve as an endpoint in addition
to bidirectional conduction block into and out of PVs (8).
However, the study did not address whether additional
application of RF energy necessary to achieve unexcitability
would translate to an improved clinical outcome.
Comparison with our pilot study. As in our prior study,
we found that a smaller electrogram amplitude generally
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49correlated with an unexcitable line; however, electrogram
amplitude alone did not reliably distinguish between excit-
able and unexcitable sites, and a clinically relevant cutpoint
was not identiﬁable in our data. In part, this is related to
the presence of signiﬁcant far-ﬁeld signals, commonly seen
at the LAA/left superior PV ridge and roof of the right
superior PV.
Similar to the prior study, we found that once the
anatomic lesion set was completed, more than 50% of PV
pairs required additional ablation for electrical isolation.
Of those that required additional ablation, 97% of PV pairs
could be isolated with pace guidance; however, a small
number required additional input from a CMC. Also
consistent with the prior study, we found that a signiﬁcant
amount of ablation energy, beyond that required for
achieving disappearance of PV electrograms, was required to
render the PV ablation line unexcitable and that the regions
requiring more ablation were often in areas where poor
contact has been commonly documented, such as the ante-
rior portion of the left PVs and the LA roof (14).
Poor arrhythmia-free survival in the conventional
group. In the present study, we observed an 82% arrhythmia-
free survival in patients with the additional endpoint of
ablation line unexcitability compared with a 52% arrhythmia-
free survival in patients with electrical PVI alone. In
comparison, patients with drug-resistant PAF in the Ther-
mocool study showed a 63% arrhythmia-free survival at
9 months in the ablation arm without routine ambulatory
ECG monitoring (15). Also included in the Thermocool
study were 12% of patients with a second procedure and
7.5% who continued to take antiarrhythmic medication. The
relatively disappointing single-procedure, arrhythmia-free
survival seen in the conventional group is similar to that seen in
the Thermocool study and other recent trials (16,17). In
accordance with the current guidelines, the patients in this
study underwent 3- to 7-day ECG monitoring every 3
months, such thatmore recurrencesmay have been detected as
compared with trials with less intensive monitoring (18).
Clinical implications: endpoint of unexcitable line
improved arrhythmia-free survival. The striking differ-
ence in recurrence rates between the pace-guided and
conventional groups was substantial and suggests that PVI is
often achieved after suboptimal lesions that are likely to
allow recurrent conduction. Additional evidence for inade-
quate lesion delivery from the present study is the ﬁnding
that <40% of PV pairs were isolated after an anatomically
complete lesion set. In a recent study in swine, ablation
lesions were much more likely to be uniform and transmural
when rendered unexcitable (9), suggesting that this endpoint
provides an indirect assessment of lesion quality. The better
single-procedure success in the pace-guided group, there-
fore, suggests that a more durable lesion set is created by
rendering the ablation line unexcitable. Other attempts to
prevent conduction gaps include a longer waiting period and
administration of adenosine, which has been shown to
facilitate “dormant” venoatrial conduction. Yamane et al. (3)were able to show that an additional waiting period of
60 min along with RF application in case of dormant
conduction reduced recurrence rates of PAF by 10%. It is
reasonable to speculate that a longer waiting period and/or
demonstration of persistent PVI with adenosine injection
might have similar beneﬁt. Pacing to assess block has some
advantages. It can be easily performed with all present
systems. It does not rely on additional waiting time. It
may help reduce application of ineffective lesions at sites
with poor catheter contact because capture likely indicates
reasonable catheter contact.
In the study of Yamane et al., the researchers were able to
show that the predominant sites of reconnection were
around the superior veins, which is consistent with the data
of the present study in which the ridge of the LAA/left
superior PV and the top of the right superior PV were the
sites that required more RF to achieve unexcitability to
pacing. Further investigations are warranted to determine
the relative contribution of adenosine response, longer
waiting periods, and an unexcitable ablation line to a more
durable ablation line.
Study limitations. We did not test whether a longer waiting
time at the completion of the procedure would have identiﬁed
sites where local edema or atrial myocardial stunning may
have contributed to the endpoint of unexcitability.
Conclusions
The use of pacing to ensure unexcitability along the PVI line
markedly improved long-term, single-procedure success,
compared with demonstration of bidirectional block alone,
with the same low rate of complications using a standard
approach. The ﬁndings of the present study underscore the
perception that PV entrance block alone may not be sufﬁcient
to achieve satisfactory clinical results for catheter ablation of
PAF. The use of this simple endpoint in addition to PVI has
the potential to signiﬁcantly improve patient outcomes.
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